IL-2 gene polymorphisms affect tacrolimus response in myasthenia gravis

Area of Science:

• Immunogenetics
• Pharmacogenomics
• Autoimmune Diseases

Background:

• Interleukin-2 (IL-2) gene polymorphisms are implicated in autoimmune disease development.
• No prior studies have investigated the impact of IL-2 gene polymorphisms on tacrolimus (Tac) response in myasthenia gravis (MG).

Purpose of the Study:

• To explore the association between IL-2 gene polymorphisms and tacrolimus treatment response in myasthenia gravis patients.
• To identify specific IL-2 genetic markers that predict tacrolimus efficacy in MG.

Main Methods:

• Genotyping of four IL-2 single-nucleotide polymorphisms (SNPs: rs2069776, rs2069772, rs2069762, rs2069763) in 92 MG patients.
• Analysis of genotype, allelic, and haplotype frequencies in tacrolimus-effective (n=57) versus tacrolimus-ineffective (n=35) patient groups.

Main Results:

• A significant difference in the allelic frequency of the rs2069762 variant was observed between effective and ineffective tacrolimus responders (P=0.02).
• The rs2069762 G/T and G/G genotypes were significantly associated with poor tacrolimus response compared to the T/T genotype (P<0.001 and P=0.003, respectively).
• The TAGG haplotype in the IL-2 gene was linked to a reduced likelihood of tacrolimus effectiveness (P<0.001, OR=0.15).

Conclusions:

• Myasthenia gravis patients possessing the rs2069762 variant, specifically the G/T and G/G genotypes, or the TAGG haplotype of the IL-2 gene, demonstrate a tendency for poorer response to tacrolimus.
• These genetic markers may serve as predictive indicators for tacrolimus treatment outcomes in myasthenia gravis.
• Further research can explore the clinical utility of IL-2 genotyping for optimizing tacrolimus therapy in MG.